Recursion Pharmaceuticals Inc. stocks have been trading down by -4.43 percent after AI drug-discovery partnership concerns ...

AI can process extraordinary quantities of information and detect patterns across them, but it does not experience ...

A fact I recently learnedI recently finished reading a book on automata, and according to that book, Turing machines, lambda calculus, and recursive functions all have the same computational ...

Right now, leading artificial intelligence models need human supervision to improve—but a popular theory known as "recursive ...

"AI will start creating smarter AI on its own."Hearing that might sound a bit like science fiction.But right now, the concept ...

I am an advocate for AI and the vast possibilities for advancement it can bring across the world. Yet, these advancements ...

Australia said on Thursday, September 24, that an OpenAI agent breached a government health data portal in June and gained unauthorised access to files. The incident could represent the first known ...

OpenAI has made an argument in favor of coordinated and global guidelines that will guide the development of AI in its next phase of development, specifically focusing on recursive self-improvement ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Richard Socher exited stealth to launch Recursive Superintelligence with $650 million, pursuing a recursive self improving AI that autonomously finds and repairs its own weaknesses while stressing red ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.